Source comparison
CJC-1295 no DAC & Ipamorelin: 2026 Cost Comparison
Premium (COA + HPLC) $85–$95 $68–$78 $360–$424 Third-party HPLC + MS $380–$450 Highest purity documentation, lowest degradation risk. Worth the premium for multi-month protocols Mid-Tier (Supplier COA) $72–$84 $56–$67 $296–$372 Supplier in-house testing $320–$
This comparison does not assign a generated winner or score.
- Premium (COA + HPLC)
- $85–$95
- $68–$78
- $360–$424
- Third-party HPLC + MS
- $380–$450
- Highest purity documentation, lowest degradation risk. Worth the premium for multi-month protocols
- Mid-Tier (Supplier COA)
- $72–$84
- $56–$67
- $296–$372
- Supplier in-house testing
- $320–$400
- Acceptable for shorter research windows (8–12 weeks); verify batch consistency
- Budget (No Verification)
- $58–$70
- $42–$54
- $228–$288
- No documented testing
- $250–$320
- Significant potency variability; peptide degradation reported 30–40% higher than premium tier
- This comparison assumes the standard research dosing protocol: CJC-1295 no DAC at 100mcg three times weekly, Ipamorelin at 200mcg three times weekly. Premium-tier suppliers include Real Peptides' CJC-1295/Ipamorelin combo vials, which provide both peptides pre-mixed in precise ratios with full third-party COA documentation. Mid-tier suppliers typically provide supplier-generated COAs without independent verification, creating potency risk. Budget suppliers frequently source peptides from uncertified synthesis facilities, leading to batch-to-batch purity swings of 8–15%. Enough to compromise research outcomes entirely.